Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

被引:0
|
作者
Yilmaz, Mukaddes [1 ]
Basak, Mustafa [2 ]
Ozyukseler, Deniz Tataroglu [3 ]
Yildirim, Mahmut Emre [4 ]
Arik, Zafer [5 ]
Salman, Mehmet Coskun [6 ]
Gultekin, Murat [6 ]
Akgor, Utku [7 ]
Inci, Bediz Kurt [8 ]
Gurler, Fatih [9 ]
Yucel, Kadriye Bir [10 ]
Savas, Gozde [10 ]
Onan, Mehmet Anil
Sunar, Veli [12 ]
Meydanli, Mehmet Mutlu [11 ,13 ]
Yazici, Ozan
Ozet, Ahmet [10 ]
机构
[1] Sivas Cumhuriyet Univ, Dept Med Oncol, Fac Med, Sivas, Turkiye
[2] Gazi Osman Pasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkiye
[3] Fethi Sekin State Hosp, Dept Med Oncol, Elazig, Turkiye
[4] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
[5] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkiye
[6] Hacettepe Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[7] Ankara Numune Training & Res Hosp, Dept Gynecol Oncol, Ankara, Turkiye
[8] Kirsehir Training & Res Hosp, Dept Med Oncol, Kirsehir, Turkiye
[9] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Med Oncol, Ankara, Turkiye
[10] Gazi Univ, Dept Med Oncol, Fac Med, Ankara, Turkiye
[11] Gazi Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[12] Aydin Ataturk State Hosp, Dept Med Oncol, Aydin, Turkiye
[13] Med Pk Hosp, Dept Gynecol Oncol, Gaziantep, Turkiye
来源
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY | 2023年
关键词
Interval debulking; neoadjuvant chemotherapy; ovarian carcinoma; primary debulking; CANCER; SURVIVAL; CYTOREDUCTION; OUTCOMES;
D O I
10.5505/tjo.2023.3883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE The aim of the study is to compare treatment outcomes of the patients with federation of gynecology and obstetrics stages III and IV ovarian carcinomas, who underwent interval debulking surgery after neoadjuvant chemotherapy (NACT), and patients who underwent adjuvant chemotherapy after primary debulking surgery (PDS). METHODS Patients from four centers (n=183) were retrospectively evaluated. Of the patients, 91 (50%) were in the PDS group and 92 (50%) in the NACT group. RESULTS In the NACT group patients have advanced age, poor performance status, high levels of CA125, and advanced disease stage compared with the PDS group (p<0.050). Of the patients receiving NACT, 14 (15%) had a complete response, and 68 (74%) had a partial response. The R0 rate was higher in the PDS group (p=0.018). In univariate analysis, poor prognostic factors affecting OS were NACT in the treatment protocol (p<0.001), poor performance status (p<0.001), advanced age (<70 vs. >= 70, p=0.002), advanced clinical stage (p=0.042), and localization of the tumor with the largest diameter outside the omentum and ovary at the time of diagnosis (p=0.029). In the multivariate analysis, the presence of NACT (HR: 2.30, 95% CI: 1.25-4.23, p=0.007) and poor performance (HR: 2.52, 95% CI: 1.18-5.10, p=0.017) were independent poor prognostic factors for OS. CONCLUSION In the study, OS was better in the PDS group than in the NACT group. This result was thought to be associated with the NACT group having more disadvantageous characteristics (advanced age, poor performance, high CA125 level, advanced stage, etc.).
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [1] Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Trope, Claes G.
    Elstrand, Mari B.
    Sandstad, Berit
    Davidson, Ben
    Oksefjell, Halldis
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2146 - 2154
  • [2] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Hong Zheng
    Yu-Nong Gao
    ChineseJournalofCancerResearch, 2012, 24 (04) : 304 - 309
  • [3] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Zheng, Hong
    Gao, Yu-Nong
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (04) : 304 - 309
  • [4] Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
    Sorensen, Sarah Mejer
    Hogdall, Claus
    Mosgaard, Berit Jul
    Dalgaard, Maya Isabella Riise
    Jensen, Mai Partridge
    Fuglsang, Katrine
    Schnack, Tine Henrichsen
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2022, 101 (03) : 334 - 343
  • [5] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Bian, Ce
    Yao, Kui
    Li, Li
    Yi, Tao
    Zhao, Xia
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 293 (01) : 163 - 168
  • [6] How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma
    Vergote, Ignace B.
    Van Nieuwenhuysen, Els
    Vanderstichele, Adriaan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) : 3827 - +
  • [7] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
    Rauh-Hain, J. Alejandro
    Rodriguez, Noah
    Growdon, Whitfield B.
    Goodman, A. K.
    Boruta, David M., II
    Horowitz, Neil S.
    del Carmen, Marcela G.
    Schorge, John O.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (03) : 959 - 965
  • [8] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Ce Bian
    Kui Yao
    Li Li
    Tao Yi
    Xia Zhao
    Archives of Gynecology and Obstetrics, 2016, 293 : 163 - 168
  • [9] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Seward, Shelly M.
    Winer, Ira
    CANCER AND METASTASIS REVIEWS, 2015, 34 (01) : 5 - 10
  • [10] Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery An Italian Multicenter Retrospective Study
    Gadducci, Angiolo
    Cosio, Stefania
    Zizioli, Valentina
    Notaro, Sara
    Tana, Roberta
    Panattoni, Andrea
    Sartori, Enrico
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (01) : 28 - 36